About Balt Group
Balt Group is a Healthcare company based in Montmorency (France) founded in 1977. It operates as a neurovascular devices for stroke treatment and embolization are provided. It operates on a Direct-to-Consumer (D2C) model. The company has 50 employees. Its chief executive is Pascal Girin. Its website baltgroup.com draws about 10 thousand monthly visits. Its Indian entity Balt India Private Limited reported revenue of ₹77.65 Cr. Balt Group offers products and services including Neurovascular Devices and Peripheral Embolization Products. Its focus areas include Medical Devices, Neurovascular Devices and Peripheral Vascular Devices. Its competitors include Route 92 Medical, Autonomix, Balt, Shenzhen Yinghe Brain Science and Neuro Front and 5 more; 5 of its 10 listed competitors have raised funding.
Company details
Balt Group is recognized for pioneering neurovascular intervention devices since 1977. The company is focused on creating physician-inspired, patient-focused solutions for ischemic and hemorrhagic stroke. Additionally, innovation is extended into the peripheral vascular space, offering a broad portfolio of medical devices. Collaboration with physicians and institutions is maintained to develop elegant solutions. A commitment to sustainability is emphasized for the planet, people, products, and patients served. The mission is driven by a dedicated team working across multiple global offices.
- Headquarters Montmorency, France
- Employees 50
- SectorsHealthcare
- Phone•••• ••••
- Website baltgroup.com
- Social LinkedIn X Instagram
- Legal Name Balt India Private Limited
- Date of Incorporation 23 Sep, 2013
- Annual Revenue₹77.65 Cr
FY 2023 · +9% YoY
- Net Profit₹5.14 Cr
FY 2023 · 7% margin
- EBITDA₹8.16 Cr
FY 2023 · 11% margin
- Latest Funding Round$488.62K (USD), Grant
May 2021
- Investors
- Employee Count50
Associated legal entities of Balt Group
Balt Group operates through Balt India Private Limited (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2023) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Balt India Private Limited CIN U74120MH2013PTC248488 | Active | 23 Sep 2013 | Mumbai, Maharashtra | ₹77.7 Cr | 44 | 3 | View details |
Products & Services of Balt Group
Balt Group offers a comprehensive portfolio of products and services, including Neurovascular Devices and Peripheral Embolization Products.
Devices for ischemic and hemorrhagic stroke are provided.
Solutions for peripheral vascular embolization are offered here.
Funding Insights of Balt Group
- Total Rounds 1
- Last Round Grant — $488,616
- First Round $488,616
(May 2021)
- Investors Count 1
All 1 funding rounds of Balt Group with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| May 2021 | $488,616 | Grant | – | – |
1 investors in total: 1 institutional.
Investors in Balt Group
Balt Group has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Ministry of Economy, Finance and Industrial and Digital Sovereignty.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
- | – | economie.gouv.fr | - |
Investor details for Balt Group
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Board of directors of Balt India Private Limited (Balt Group)
Balt India Private Limited is the primary company behind Balt Group. The board of Balt India Private Limited currently have 3 directors; the longest-serving is Emeric Marie Etienne Domergue, appointed in 2018. 6 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Emeric Marie Etienne Domergue DIN 08213887 | Additional Director | 23 Nov 2018 | 7 yrs 10 mo | Balt India Private Limited |
| Sanjay Sunder Karnani DIN 08332856 | Director | 05 Mar 2019 | 7 yrs 7 mo | Balt India Private Limited |
| Peter Stuart Cooke DIN 10671230 | Director | 01 May 2024 | 2 yrs 5 mo | Balt India Private Limited |
People of Balt Group
63 people are tracked at Balt Group (28 in leadership, 35 in team); the tracked headcount is 50.
| Name | Role | Group |
|---|---|---|
Pascal Girin | CEO | Leadership |
Brian Mitchell | Vice President Of Engineering | Leadership |
Suzi Flores | Vice President, Human Resources – Americas | Leadership |
Anne-Charlotte Galimont | International Marketing Director | Leadership |
Florence Leroy | Vice President, Global Human Resources | Leadership |
Eric Largen | Vice President, Global R&d | Leadership |
Paul Laquerre | Chief Financial Officer | Leadership |
Eric Montalescot | Senior Vice President, International | Leadership |
Thomas Colson | Vice President, Global Quality | Leadership |
Jeff Sachs | Chief Legal Officer | Leadership |
Patrice Cornillon | Vice President, Global Operations | Leadership |
Moises Colin | Senior Vice President, Global Quality | Leadership |
Orli Shvartzman | Director, Corporate Financial Planning & Analysis | Leadership |
Fred Gunderman | Senior Vice President, USA | Leadership |
Ryan Solomon | Vice President, Corporate Strategy & Business Development | Leadership |
Erik Kremer | Director Global Logistics | Leadership |
Katherine Oates | Chief Of Staff | Leadership |
Armando Calderon | Vice President, Global Operations Finance | Leadership |
Claus Freyinger | Global Vice President, Regulatory, Clinical, Medical Affairs | Leadership |
Steve Sills | Director - Stroke & New Technology Sales | Leadership |
43 more people are available in the full profile.
Complete people profiles for Balt Group
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Financials of Balt Group
Figures of Balt India Private Limited, the primary company behind Balt Group, for FY 2023. Revenue was ₹77.65 Cr (+9% year on year). Net profit was ₹5.14 Cr (7% margin). EBITDA was ₹8.16 Cr (11% margin). Revenue has grown at a compounded annual rate of +29% over three years and +26% over five years.
- ₹77.65 CrRevenue · FY 2023 · +9% YoY
- ₹5.14 CrNet profit · 7% margin
- ₹8.16 CrEBITDA · 11% margin
- ₹1.00 CrPaid-up capital
- 44Employees (provident fund records)
- +29%Revenue CAGR, 3 years
- +26%Revenue CAGR, 5 years
Balance sheet, profit and loss, cash flow and ratios of Balt India Private Limited are on its company page.
Detailed financial statements for Balt Group
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Balt Group
2 dated milestones of Balt Group across 44 years, from founding to its latest funding, stage changes and deals.
- Founded Balt Group is founded.
- Funding First funding round of $489K.
Competitors of Balt Group
Balt Group has 10 listed competitors in our database, 5 of them funded. They include Route 92 Medical, Autonomix, Balt, Shenzhen Yinghe Brain Science and Neuro Front, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| route92medical.com | 2015 | San Mateo, United States | $167.15M | 51 | Next-generation products for neurointerventional procedures are developed. | |
| autonomix.com | 2014 | The Woodlands, United States | $8.2M | – | Minimally invasive neural monitoring and treatment devices are developed. | |
| balt.fr | 1977 | Montmorency, France | – | – | Interventional neuroradiology devices for vascular malformations are developed. | |
| shenzhenyinghebrainscience.tcc.mode | 2022 | China | $14.74M | – | Neuromodulation devices and brain-computer interfaces for neurological treatments are developed. | |
| neurofrontrx.com | 2020 | Pudong, China | – | – | Transformation medicines and neuromodulation devices for neurological disorders are developed. | |
| capri-medical.com | 2018 | Dublin, Ireland | – | – | Injectable neurostimulation devices are developed for neurological treatments. | |
| neurodome-med.com | 2019 | Xi An, China | – | – | Minimally invasive neurosurgical equipment and neuromodulation technologies are developed. | |
| shenzhenweilingmedicalequipment.tcc.mode | 2019 | Shenzhen, China | – | – | Implantable wireless brain-computer interfaces are developed for neural signal analysis. | |
| magnendo.com | 2024 | Boston, United States | $2.25M | – | Magnetically steerable guidewires for neurovascular disease treatments are developed. | |
| fiveliters.com | 2022 | Dallas, United States | $500,000 | – | Developer of medical device for non-invasive neuromodulation of hemorrhaging |
Detailed competitors of Balt Group
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Balt Group
The website of Balt Group (baltgroup.com) receives about 10.5K visits a month.
- Monthly visits10.5K
▼ 21.6% vs previous month
Websites whose visitors overlap most with Balt Group. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| medicalecart.com | 100% | – | #1,123,365 | View details |
Top companies in Neurology
10 companies that operate in the same segment as Balt Group (Neurology), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Novel biopharmaceutical medicines are developed for unmet medical needs. | 2003 | Dublin, Ireland | USD 265 M | USD 4.27 B | 2,800 | |
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 | |
Developer of therapeutics for psychiatric and neurologic diseases | 2002 | New York, New York, United States | USD 80.87 M | USD 250.31 M | 600 | |
Biologics platform developed for intracellular delivery in rare diseases. | 2016 | Boston, Massachusetts, United States | USD 175.25 M | USD 25.42 M | 183 | |
Developer of therapies for the treatment of musculoskeletal disorders | 2007 | Woburn, Massachusetts, United States | USD 62 M | USD 85.55 M | 692 | |
MR-interfaced ultrasound devices for cancer and neurology treatments are provided. | 1999 | Tirat Carmel, Haifa District, Israel | USD 574.2 M | – | 541 | |
AI-driven drug discovery platform for neurological diseases based on patients biomarkers | 2019 | San Francisco, California, United States | USD 144.72 M | – | 76 | |
Small molecule drugs for rare diseases are developed. | 1998 | South Plainfield, New Jersey, United States | USD 248.1 M | USD 1.73 B | 939 | |
Developer of small molecule therapeutics for endocrine and CNS disorders | 1992 | San Diego, California, United States | USD 10 M | USD 2.86 B | 1,800 | |
Developer of antibodies to treat complement-mediated neurodegenerative diseases | 2011 | San Francisco, California, United States | USD 256 M | – | 100 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Balt Group
Complete news archive for Balt Group
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Balt Group
Balt Group was founded in 1977 and raised its 1st funding round 44 years after it was founded.
Balt Group is headquartered in Montmorency, France. It is registered at Montmorency, Ile-de-france, France.
Pascal Girin is the current CEO of Balt Group.
Balt Group has 50 employees.
The primary company behind Balt Group, Balt India Private Limited, reported revenue of ₹77.65 Cr for FY 2023, up 9% year on year.
Balt Group is recognized for pioneering neurovascular intervention devices since 1977. The company is focused on creating physician-inspired, patient-focused solutions for ischemic and hemorrhagic stroke. Additionally, innovation is extended into the peripheral vascular space, offering a broad portfolio of medical devices. Collaboration with physicians and institutions is maintained to develop elegant solutions. A commitment to sustainability is emphasized for the planet, people, products, and patients served. The mission is driven by a dedicated team working across multiple global offices.
Balt Group's top competitors include Route 92 Medical, Autonomix and Magnendo.
Balt Group offers Neurovascular Devices and Peripheral Embolization Products.
Balt Group has 1 investor. Key investors include Ministry of Economy, Finance and Industrial and Digital Sovereignty.
Balt Group operates through Balt India Private Limited.
The legal entities of Balt Group currently have 3 directors, including Sanjay Sunder Karnani, Emeric Marie Etienne Domergue, Peter Stuart Cooke.